Joseph Gilliam Sells 19,573 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 19,573 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at approximately $10,538,563.26. This trade represents a 21.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Stock Down 1.8%

GKOS stock opened at $133.36 on Wednesday. The company has a market cap of $7.83 billion, a PE ratio of -40.66 and a beta of 0.94. The business has a 50-day simple moving average of $114.28 and a 200 day simple moving average of $108.35. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $146.75. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The business had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Sell-side analysts anticipate that Glaukos Corporation will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC boosted their target price on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. BTIG Research boosted their target price on Glaukos from $131.00 to $141.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. William Blair raised Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. Finally, JPMorgan Chase & Co. boosted their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.42.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Needham reiterated a Buy on Glaukos, reinforcing analyst support and underpinning upside expectations for the shares. Needham Remains a Buy on Glaukos (GKOS)
• Positive Sentiment: Media coverage highlights a shifting narrative as Glaukos gives updated guidance and signals a product ramp (sustained drug-delivery and MIGS growth), which supports upside to revenue trajectory if execution continues. How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
• Neutral Sentiment: Recent quarter: revenue beat consensus and EPS outperformed estimates on stronger sales, supporting the case for durable top-line growth even though profitability remains negative. Analysts’ price targets were raised by some firms; consensus remains a Moderate Buy. MarketBeat GKOS summary
• Neutral Sentiment: CFO Alex Thurman sold 10,000 shares under a pre-arranged Rule 10b5-1 plan, which reduces the signal of opportunistic timing but still reduces insider holdings. CFO 10b5-1 sale filing
• Negative Sentiment: COO Joseph Gilliam sold 19,573 shares (~21% reduction in his position), a large insider sale that can raise investor concern about insider confidence or portfolio rebalancing. Glaukos COO Joseph Gilliam Sells 19,573 Shares
• Negative Sentiment: Director Leana Wen sold 1,700 shares, a smaller but visible insider sale disclosed via SEC filing — another factor that can pressure near-term sentiment. Director Leana Wen Sells 1,700 Shares

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its stake in Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after acquiring an additional 336,266 shares in the last quarter. Primecap Management Co. CA raised its stake in Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after acquiring an additional 1,123,140 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Glaukos by 183.4% during the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock worth $340,855,000 after purchasing an additional 1,953,578 shares during the last quarter. State Street Corp grew its holdings in shares of Glaukos by 0.9% during the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after purchasing an additional 18,040 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after purchasing an additional 68,497 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.